Skip to main content
SpringerLink
Log in

Therapieoptionen bei blasenbildenden Autoimmunerkrankungen

  • Chapter
Fortschritte der praktischen Dermatologie und Venerologie 2006

Part of the book series: Fortschritte der praktischen Dermatologie und Venerologie ((DERMATOLOGIE,volume 20))

  • 78 Accesses

Zusammenfassung

Die Einführung systemischer Immunsuppressiva hat die Prognose des Pemphigus und weiterer bullöser Autoimmundermatosen dramatisch verbessert. Aufgrund langjähriger Erfahrung werden systemische Glukokortikoide beim Pemphigus und Pemphigoid in der Regel mit anderen Immunsuppressiva kombiniert, um Dosis und Dauer der systemischen Gabe von Glukokortikoiden schneller reduzieren zu können [8] (Tabelle 2). Die am meisten eingesetzten adjuvanten Immunsuppressiva sind Azathioprin, Chlorambucil, Cyclophosphamid, Methotrexat, Cyclosporin A und Mycophenolsäure [17] (Tabelle 1, 3). Klinische Erfahrungen bezüglich ihrer Wirksamkeit werden im folgenden kurz dargestellt.

Nutzen-Wirksamkeits-Analyse der gängigen Immunsuppressiva

Tabelle 2

Therapiestandards bei bullösen Autoimmundermatosen

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K (1987) Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol 16: 527–533

    Article  CAS  PubMed  Google Scholar 

  2. Ahmed AR, Hombal S (1987) Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol 17: 437–442

    Article  CAS  PubMed  Google Scholar 

  3. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355: 1772–1779

    Article  CAS  PubMed  Google Scholar 

  4. Arin MJ, Engert A, Krieg T, Hunzelmann N. 2005). Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153: 620–625

    Google Scholar 

  5. Blaszczyk M, Chorzelski T, Daszynski J, et al. (1981) Plasmapheresis as a supplementary treatment in pemphigus. Arch Immunol Ther Exp 29: 763–767

    CAS  Google Scholar 

  6. Böhm M, Beissert S, Schwarz T, et al. (1997) Bullous pemphigoid treated with mycophenolare mofetil. Lancet 349: 541

    Article  PubMed  Google Scholar 

  7. Borradori L, Lombardi T, Samson J, et al. (2001) Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137: 269–272

    CAS  PubMed  Google Scholar 

  8. Bystryn JC, Steinman NM (1996) The adjuvant therapy of pemphigus. An update. Arch Dermatol 132: 203–212

    Article  CAS  PubMed  Google Scholar 

  9. Crow LL, Finkle JP, Gammon WR, Woodley DT (1988) Clearing of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol 19: 937–942

    Article  CAS  PubMed  Google Scholar 

  10. Cunningham BB, Kirchmann TT, Woodley DT (1996) Colchicine for epidermolysis bullosa (EBA). J Am Acad Dermatol 34: 781–784

    Article  CAS  PubMed  Google Scholar 

  11. El Tal AK, Posner MR, Spigelman Z, Ahmed AR (2006) Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol 55: 449–459

    Article  PubMed  Google Scholar 

  12. Eming R, Hertl M (2006) Immunoadsorption in pemphigus. Autoimmunity 39: 609–616

    Article  CAS  PubMed  Google Scholar 

  13. Eming R, Niedermeier A, Pfütze, M, et al. (2007) Treating autoimmune bullous skin disorders with biologics. In: Boehncke WH, Radeke H (eds) Biologics in general medicine. Springer, Heidelberg

    Google Scholar 

  14. Eming R, Rech J, Barth S, et al. (2006) Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 212: 177–187

    Article  PubMed  Google Scholar 

  15. Enk AH, Knop J (1999) Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 135: 54–56

    Article  CAS  PubMed  Google Scholar 

  16. Beissert S, Werfel T, Frieling U, et al. (2006) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142: 1447–1454

    Article  CAS  PubMed  Google Scholar 

  17. Hertl M, Schuler G (2002) Bullöse Autoimmundermatosen. Teil 3: Diagnostik und Therapie. Hautarzt 53: 352–365

    Article  CAS  PubMed  Google Scholar 

  18. Ioannides D, Chrysomallis F, Bystryn JC (2000) Ineffectiveness of cyclosporine as adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 136: 868–872

    CAS  PubMed  Google Scholar 

  19. Jackson AP, Hall AG, McLelland J (1997) Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br J Dermatol 136: 133–134

    Article  CAS  PubMed  Google Scholar 

  20. Jolles S (2001) A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Dermatol 26: 127–131

    Article  CAS  Google Scholar 

  21. Joly P, Roujeau JC, Benichou J, et al. (2002) Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous Pemphigoid. N Engl J Med 346: 321–327

    Article  CAS  PubMed  Google Scholar 

  22. Leandro MJ, Cooper N, Cambridge G, et al. (2006) Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 46: 29–36

    Article  Google Scholar 

  23. Lüftl M, Stauber A, Mainka A, et al. (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149: 598–605

    Article  PubMed  Google Scholar 

  24. Niedermeier A, Worl P, Barth S, et al. (2006) Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 16: 266–270

    PubMed  Google Scholar 

  25. Niedermeier A, Eming R, Pfütze M, et al. (2007) Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibody). Arch. Dermatol (in press)

    Google Scholar 

  26. Pasricha JS, Thanzama J, Khan UK (1988) Intermittent highdose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 119: 73–77

    Article  CAS  PubMed  Google Scholar 

  27. Rogers RS, Seehafer JR, Perry HO (1982) Treatment of cicatricial pemphigoid with dapsone. J Am Acad Dermatol 6: 215–223

    Article  PubMed  Google Scholar 

  28. Rouziere AS, Kneitz C, Palanichamy A, et al. (2005) Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 7: R714–724

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Schmidt E, Klinker E, Opitz A, et al. (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe Pemphigus. Br J Dermatol 148: 1222–1229

    Article  CAS  PubMed  Google Scholar 

  30. Schmidt E, Benoit S, Brocker EB, et al. (2006) Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 142: 147–150

    Article  PubMed  Google Scholar 

  31. Shimanovich I, Herzog S, Schmidt E, et al. (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31: 768–774

    Article  CAS  PubMed  Google Scholar 

  32. Toth GG, Jonkman MF (2001) Therapy of pemphigus. Clin Dermatol 19: 761–767

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Hautkrankheiten, Klinikum der Philipps-Universität, Deutschhausstraße 9, 35037, Marburg, Germany

    Prof. Dr. med. Michael Hertl & Dr. med. Rüdiger Eming

Authors
  1. Prof. Dr. med. Michael Hertl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Rüdiger Eming
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Frauenlobstraße 9-11, 80337, München, Germany

    Gerd Plewig  & Peter Thomas  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Hertl, M., Eming, R. (2007). Therapieoptionen bei blasenbildenden Autoimmunerkrankungen. In: Plewig, G., Thomas, P. (eds) Fortschritte der praktischen Dermatologie und Venerologie 2006. Fortschritte der praktischen Dermatologie und Venerologie, vol 20. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-30515-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-30515-6_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-30514-9

  • Online ISBN: 978-3-540-30515-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation